American Bio Medica Corp (ABMC) SEC Filing 8-K Material Event for the period ending Thursday, April 6, 2017

American Bio Medica Corp

CIK: 896747 Ticker: ABMC










Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): April 6, 2017




(Exact name of registrant as specified in its charter)


New York   0-28666   14-1702188
(State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification Number)


122 Smith Road, Kinderhook, NY           12106


(Address of principal executive offices)           (Zip Code)


Registrant’s telephone number, including area code: 518-758-8158


Not applicable


(Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


¨   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Item 1.01Entry into a Material Definitive Agreement


On April 10, 2017, American Bio Medica Corporation (the “Company”) entered into an addendum to the Financial Advisory Agreement (the “Agreement”) with Landmark Pegasus, Inc. (“Landmark”). The Agreement provides that Landmark will continue to provide certain financial advisory services for a minimum period of 6 months (which period commenced on April 10, 2017), and as consideration for these services, the Company will pay Landmark (a) a retainer fee of $50,000 payable in 454,545 restricted shares of common stock and (b) certain “success fees” for the consummation of any transaction closing during the term of the Agreement and for 12 months thereafter, between the Company and any party first introduced to the Company by Landmark, or for any other transaction not originated by Landmark but for which Landmark provides substantial support in completing during the term of the Agreement. There is no material relationship between the Company and Landmark, other than with respect to the Agreement.


On October 25, 2016, Landmark filed a Schedule 13G in connection with its greater than 5% ownership of the Company’s total shares outstanding.


Item 5.02Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers


On April 6, 2017, Richard P. Koskey and Carl A. Florio informed the Board of their decision to resign from their positions from the Company’s Board of Directors. Mr. Koskey and Mr. Florio provided the Company with their resignations in writing and their letters did not contain any statements describing disagreements with the Company related to its operations, policies or practices, nor did any such disagreement lead to either Mr. Koskey’s or Mr. Florio’s resignation. Mr. Koskey has served on the Board of Directors since 2003 and Mr. Florio has served on the Board of Directors since 2004. Mr. Koskey has served as the Chairman of the Board since December 2014 in addition to his memberships on the Nominating, Compensation and Audit Committees of the Board of Directors. Mr. Florio also served as a member of the same three committees.


The remaining members of the Board of Directors, (Jean Neff, Diane Generous and Company Chief Executive Officer/Principal Financial Officer Melissa Waterhouse) determined that the Board of Directors would review a list of potential candidates to fill the vacancies created on the Board of Directors by the resignations. In absence of the appointment of a new Chairman of the Board and until a new Chairman is appointed, the Company’s Chief Executive Officer, Melissa Waterhouse will assume the responsibilities of the Chairman of the Board under the Company’s Bylaws.







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: April 11, 2017 By:  /s/ Melissa A. Waterhouse  
    Melissa A. Waterhouse
Chief Executive Officer
(Principal Executive Officer)
Principal Financial Officer





View differences made from one to another to evaluate American Bio Medica Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by American Bio Medica Corp.


Assess how American Bio Medica Corp's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

American Bio Medica Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


Ticker: ABMC
CIK: 896747
Form Type: 8-K Corporate News
Accession Number: 0001144204-17-020010
Submitted to the SEC: Tue Apr 11 2017 3:49:39 PM EST
Accepted by the SEC: Tue Apr 11 2017
Period: Thursday, April 6, 2017
Industry: Pharmaceutical Preparations
  1. Event for Officers
  2. New Agreement

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: